Yousef Zakharia, MD, discussed recent phase I data from a study of seleno-L-methionine in combination with axitinib as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma. Zakharia recently presented these data as part of the American Urological Association Virtual Experience platform for the 2020 AUA Annual Meeting.
Yousef Zakharia, MD, associate professor of medicine, University of Iowa, Holden Comprehensive Cancer Center, discussed recent phase I data from a study of seleno-L-methionine (SLM) in combination with axitinib (Inlyta) as treatment of patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC). Zakharia recently presented these data as part of the American Urological Association (AUA) Virtual Experience platform for the 2020 AUA Annual Meeting.
Out of 15 evaluable patients with ccRCC who progressed on one or more prior lines of treatment, responses were seen across all cohorts of patients who received SLM in combination with axitinib. Overall responses were seen in 53% of patients (n = 8). Complete responses (CRs) were observed in 2 patients. CRs for these patients were still ongoing at 31 and 29 months, respectively. Partial responses were observed in 6 patients, with a disease control rate of about 73%. Some responses lasted for more than 3 years.
There were no dose-limiting toxicities in the study. Most commonly, adverse events (AEs) were grades 1 and 2.The most common AEs that patients experienced were fatigue, diarrhea, hypertension, nausea, anorexia, cough, proteinuria, and weight loss. The most common grade 3 or 4 AE was hypertension. These AEs were consistent with the known toxicity of axitinib. No grade 4 and 5 toxicities were observed.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More